Nuclear Medicine Department, Beijing Friendship Hospital, Capital Medical University, 95 Yong'an Road, Xicheng District, Beijing, 100050, China.
Department of Nuclear Medicine, The First Medical Center, Chinese PLA General Hospital, No. 28 Fuxing Road, Haidian District, Beijing, 100853, China.
BMC Cancer. 2022 Aug 16;22(1):895. doi: 10.1186/s12885-022-09988-1.
To evaluate the diagnostic performance of combined multiparametric F-fluorodeoxyglucose positron emission tomography (FDG PET) with clinical characteristics in differentiating thymic epithelial tumors (TETs) from thymic lymphomas.
A total of 173 patients with 80 TETs and 93 thymic lymphomas who underwent F-FDG PET/CT before treatment were enrolled in this retrospective study. All patients were confirmed by pathology, and baseline characteristics and clinical data were also collected. The semi-parameters of F-FDG PET/CT, including lesion size, SUVmax (maximum standard uptake value), SUVmean (mean standard uptake value), TLG (total lesion glycolysis), MTV (metabolic tumor volume) and SUVR (tumor-to-normal liver standard uptake value ratio) were evaluated. The differential diagnostic efficacy was evaluated using the receiver operating characteristic (ROC) curve. Integrated discriminatory improvement (IDI) and net reclassification improvement (NRI), and Delong test were used to evaluate the improvement in diagnostic efficacy. The clinical efficacy was evaluated by decision curve analysis (DCA).
Age, clinical symptoms, and metabolic parameters differed significantly between patients with TETs and thymic lymphomas. The ROC curve analysis of SUVR showed the highest differentiating diagnostic value (sensitivity = 0.763; specificity = 0.888; area under the curve [AUC] = 0.881). The combined diagnostics model of age, clinical symptoms and SUVR resulted in the highest AUC of 0.964 (sensitivity = 0.882, specificity = 0.963). Compared with SUVR, the diagnostic efficiency of the model was improved significantly. The DCA also confirmed the clinical efficacy of the model.
The multiparameter diagnosis model based on F-FDG PET and clinical characteristics had excellent value in the differential diagnosis of TETs and thymic lymphomas.
评估 F-氟代脱氧葡萄糖正电子发射断层扫描(FDG PET)与临床特征联合用于鉴别胸腺瘤(TET)与胸腺癌的诊断性能。
本回顾性研究纳入了 173 例经治疗前 F-FDG PET/CT 检查的 80 例 TET 和 93 例胸腺癌患者。所有患者均经病理证实,并收集了基线特征和临床数据。评估了 FDG PET/CT 的半参数,包括病变大小、SUVmax(最大标准摄取值)、SUVmean(平均标准摄取值)、TLG(总病灶糖酵解)、MTV(代谢肿瘤体积)和 SUVR(肿瘤与正常肝脏标准摄取值比值)。使用受试者工作特征(ROC)曲线评估鉴别诊断效能。使用综合判别改善(IDI)和净重新分类改善(NRI)以及 Delong 检验评估诊断效能的改善。使用决策曲线分析(DCA)评估临床疗效。
TET 患者与胸腺癌患者的年龄、临床症状和代谢参数存在显著差异。SUVR 的 ROC 曲线分析显示出最高的鉴别诊断价值(敏感性=0.763;特异性=0.888;曲线下面积[AUC]=0.881)。年龄、临床症状和 SUVR 的联合诊断模型的 AUC 最高,为 0.964(敏感性=0.882,特异性=0.963)。与 SUVR 相比,该模型的诊断效率显著提高。DCA 也证实了该模型的临床疗效。
基于 F-FDG PET 和临床特征的多参数诊断模型在 TET 和胸腺癌的鉴别诊断中具有优异的价值。